Two BLAs, One Suffix: FDA Diverges From Nonproprietary Naming Guidance For Amgen’s Wezlana

 
• By Sue Sutter
Drug Review Profile: Wezlana
The two Wezlana BLAs ended up with the same nonproprietary name suffix. • Source: Shutterstock

More from Drug Review Profiles

More from Product Reviews